Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00518661 · ClinicalTrials.gov registry record
Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 500
- Enrollment target
NCT00518661 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 500 participants.
The verdict
NCT00518661 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
Study Summary
This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2007-08 |
| Est. Completion | 2017-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00518661
The ClinicalTrials.gov registry entry for NCT00518661 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00518661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00518661 about?
NCT00518661 is a clinical study titled "Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species". This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.
What is the current status of trial NCT00518661?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2007-08. Estimated completion is 2017-12.
Who is sponsoring clinical trial NCT00518661?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.